Cargando…
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
Management of patients with metastatic hormone receptor-positive breast cancer poses a challenge due to the inevitable development of endocrine resistance. Hormone resistance is associated with a complex interaction of the estrogen receptor with growth factors, transmembrane receptors, and intracell...
Autores principales: | Paplomata, Elisavet, O’Regan, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549674/ https://www.ncbi.nlm.nih.gov/pubmed/23345981 http://dx.doi.org/10.2147/TCRM.S30349 |
Ejemplares similares
-
Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013) -
PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
por: Dhakal, Ajay, et al.
Publicado: (2021) -
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
por: Mitri, Zahi, et al.
Publicado: (2012) -
Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017) -
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
por: Lui, Asona, et al.
Publicado: (2016)